140 related articles for article (PubMed ID: 11293392)
1. Statin-fibrate combinations in patients with combined hyperlipedemia.
Athyros VG; Papageorgiou AA; Kontopoulos AG
Atherosclerosis; 2001 Mar; 155(1):263-4. PubMed ID: 11293392
[No Abstract] [Full Text] [Related]
2. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Athyros VG; Papageorgiou AA; Hatzikonstandinou HA; Didangelos TP; Carina MV; Kranitsas DF; Kontopoulos AG
Am J Cardiol; 1997 Sep; 80(5):608-13. PubMed ID: 9294990
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Pehlivanidis AN; Kontopoulos AG
J Cardiovasc Risk; 2002 Feb; 9(1):33-9. PubMed ID: 11984215
[TBL] [Abstract][Full Text] [Related]
4. [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].
Zeman M; Zák A; Vecka M; Romaniv S
Cas Lek Cesk; 2003 Aug; 142(8):500-4. PubMed ID: 14626567
[TBL] [Abstract][Full Text] [Related]
5. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Alford JC; Saseen JJ; Allen RR; Nair KV
Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia.
Ellen RL; McPherson R
Am J Cardiol; 1998 Feb; 81(4A):60B-65B. PubMed ID: 9526816
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Bruckert E; De Gennes JL; Malbecq W; Baigts F
Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of familial combined hyperlipidemia].
Bruckert E
Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478
[No Abstract] [Full Text] [Related]
10. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.
Wang TD; Chen WJ; Lin JW; Cheng CC; Chen MF; Lee YT
Atherosclerosis; 2003 Oct; 170(2):315-23. PubMed ID: 14612213
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia.
Kayikçioğlu M; Ozerkan F; Soydan I
Am J Cardiol; 1999 Apr; 83(7):1135-7, A9. PubMed ID: 10190536
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.
Oldemeyer JB; Lund RJ; Koch M; Meares AJ; Dunlay R
Cardiology; 2000; 94(2):127-8. PubMed ID: 11173785
[TBL] [Abstract][Full Text] [Related]
13. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
Mikhailidis DP; Jagroon IA
Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
[No Abstract] [Full Text] [Related]
14. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
[TBL] [Abstract][Full Text] [Related]
15. Effects of various fibrates on serum alkaline phosphatase activity.
Ganotakis E; Tsimihodimos V; Bairaktari E; Rizos E; Athyros V; Seferiades C; Elisaf M
Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
[No Abstract] [Full Text] [Related]
16. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks.
Farnier M
Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929
[TBL] [Abstract][Full Text] [Related]
17. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Grundy SM
Am J Cardiol; 1998 Feb; 81(4A):1B-6B. PubMed ID: 9526806
[No Abstract] [Full Text] [Related]
18. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
[TBL] [Abstract][Full Text] [Related]
19. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
[TBL] [Abstract][Full Text] [Related]
20. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Choi IS; Shin EK
J Am Coll Cardiol; 2005 May; 45(10):1649-53. PubMed ID: 15893182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
